专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

11. 发明授权

US08349558B2 Detection of individual T-cell reaction patterns against tumor-associated antigens (TAA) in tumor patients as a basis for the individual therapeutic vaccination of patients 有权
标题翻译：在肿瘤患者中检测针对肿瘤相关抗原（TAA）的单个T细胞反应模式作为患者个体治疗性接种的基础
公开(公告)号：US08349558B2
公开(公告)日：2013-01-08
申请号：US12519315
申请日：2007-11-28
申请人： Martina Fatho , Emmanuelle Wesarg , Volker Lennerz , Pierre Van Der Bruggen , Thomas Wölfel , Serena Debo
发明人： Martina Fatho , Emmanuelle Wesarg , Volker Lennerz , Pierre Van Der Bruggen , Thomas Wölfel , Serena Debo
IPC分类号： C12N33/48 , C12N5/02 , G01N33/48 , C12N5/10
CPC分类号： C07K14/4748 , G01N33/505 , G01N2333/70539
摘要： The present invention relates to a method for identifying the preferential target antigens of antitumoural T-cells of a tumour patient, comprising: a) providing T-cells from the blood of at least one tumour patient, b) providing dendritic cell (DCs) and/or B-lymphocytes (BLCs) that are autologous for said tumour patient, wherein said DCs and BLCs were transfected beforehand with a selection of mRNAs encoding for T-cell-immunogenic tumour-associated antigens (TAA), and express these, c) contacting said T-cells with the DCs and/or BLCs, d) identifying of those T-cells that recognize antigens of the DCs and/or BLCs, and e) identifying of the preferential target antigens of antitumoural T-cells of the at least one tumour patient on the basis of the T-cells that recognize antigens of the DCs and/or BLCs. The method can furthermore comprise the expansion of the T-cells that recognize the antigens of the DCs and/or BLCs. The present invention furthermore relates to a method for producing an individualized tumour vaccine or individualized tumour therapeutic, as well as corresponding methods for treating a tumourous disease using the individualised tumour vaccine or individualised tumour therapeutic.
摘要翻译：本发明涉及用于鉴定肿瘤患者的抗肿瘤T细胞的优先靶抗原的方法，包括：a）从至少一个肿瘤患者的血液提供T细胞，b）提供树突状细胞（DC）和或所述肿瘤患者自体的B淋巴细胞（BLC），其中所述DC和BLC预先用编码T细胞免疫原性肿瘤相关抗原（TAA）的mRNA的选择进行转染，并表达这些，c）使所述T细胞与DC和/或BLC接触，d）识别识别DC和/或BLC的抗原的那些T细胞，以及e）至少鉴定所述T细胞的抗肿瘤T细胞的优先靶抗原一个肿瘤患者基于识别DC和/或BLC的抗原的T细胞。该方法还可以包括识别DC和/或BLC的抗原的T细胞的扩增。本发明还涉及一种用于产生个体化肿瘤疫苗或个体化肿瘤治疗剂的方法，以及使用个体化肿瘤疫苗或个体化肿瘤治疗剂治疗肿瘤疾病的相应方法。

12. 发明授权

US5925729A Tumor rejection antigen precursors, tumor rejection antigens and uses thereof 失效
标题翻译：肿瘤排斥抗原前体，肿瘤排斥抗原及其用途
公开(公告)号：US5925729A
公开(公告)日：1999-07-20
申请号：US142368
申请日：1994-05-02
申请人： Thierry Boon , Pierre Van Der Bruggen , Benoit Van Den Eynde , Aline Van Pel , Etienne De Plaen , Christophe Lurquin , Patrick Chomez , Catia Traversari
发明人： Thierry Boon , Pierre Van Der Bruggen , Benoit Van Den Eynde , Aline Van Pel , Etienne De Plaen , Christophe Lurquin , Patrick Chomez , Catia Traversari
IPC分类号： A61K31/70 , A61K9/127 , A61K35/12 , A61K35/14 , A61K35/18 , A61K38/00 , A61K39/00 , A61K39/395 , A61K48/00 , A61P35/00 , C07K7/06 , C07K14/00 , C07K14/47 , C07K14/52 , C07K14/525 , C07K14/54 , C07K14/55 , C07K14/705 , C07K16/00 , C07K16/30 , C07K16/42 , C07K17/00 , C12N1/00 , C12N1/20 , C12N1/21 , C12N5/10 , C12N7/00 , C12N15/00 , C12N15/02 , C12N15/09 , C12N15/12 , C12P21/02 , C12P21/08 , C12Q1/00 , C12Q1/68 , C12R1/19 , G01N33/50 , G01N33/53 , G01N33/574 , G01N33/577 , G01N33/68 , A61K38/08
CPC分类号： C07K14/4748 , C07K16/30 , A61K38/00 , A61K39/00 , Y10S530/806 , Y10S530/828
摘要： The invention relates to an isolated DNA sequence which codes for an antigen expressed by tumor cells which is recognized by cytotoxic T cells, leading to lysis of the tumor which expresses it. Also described are cells transfected by the DNA sequence, and various therapeutic and diagnostic uses arising out of the properties of the DNA and the antigen for which it codes.
摘要翻译：本发明涉及编码由细胞毒性T细胞识别的肿瘤细胞表达的抗原的分离的DNA序列，导致表达肿瘤的裂解。还描述了由DNA序列转染的细胞，以及由其编码的DNA和抗原的性质产生的各种治疗和诊断用途。

13. 发明授权

US07923534B1 Isolated tumor rejection antigen precursor proteins MAGE-2 and MAGE-3 失效
标题翻译：分离的肿瘤排斥抗原前体蛋白MAGE-2和MAGE-3
公开(公告)号：US07923534B1
公开(公告)日：2011-04-12
申请号：US08819669
申请日：1997-03-17
申请人： Thierry Boon , Pierre Van Der Bruggen , Benoit Van Den Eynde , Aline Van Pel , Etienne De Plaen , Christophe Lurquin , Patrick Chomez , Catia Traversari
发明人： Thierry Boon , Pierre Van Der Bruggen , Benoit Van Den Eynde , Aline Van Pel , Etienne De Plaen , Christophe Lurquin , Patrick Chomez , Catia Traversari
IPC分类号： C07K14/435
CPC分类号： C07K14/4748 , A61K38/00 , A61K39/00 , C07K16/30 , Y10S530/806 , Y10S530/828
摘要： The invention relates to an isolated DNA sequence which codes for an antigen expressed by tumor cells which is recognized by cytotoxic T cells, leading to lysis of the tumor which expresses it. Also described are cells transfected by the DNA sequence, and various therapeutic and diagnostic uses arising out of the properties of the DNA and the antigen for which it codes.
摘要翻译：本发明涉及编码由细胞毒性T细胞识别的肿瘤细胞表达的抗原的分离的DNA序列，导致表达肿瘤的裂解。还描述了由DNA序列转染的细胞，以及由其编码的DNA和抗原的性质产生的各种治疗和诊断用途。

14. 发明申请

US20090104186A1 Melanoma-associated MHC class I associated oligopeptides and the uses thereof 审中-公开
标题翻译：黑素瘤相关的MHC I类相关寡肽及其用途
公开(公告)号：US20090104186A1
公开(公告)日：2009-04-23
申请号：US11991339
申请日：2006-08-31
申请人： Daniela Eberts , Martina Fatho , Volker Lennerz , Chris Schmidt , Pierre Van Der Bruggen , Catherine Wolfel , Thomas Wolfel
发明人： Daniela Eberts , Martina Fatho , Volker Lennerz , Chris Schmidt , Pierre Van Der Bruggen , Catherine Wolfel , Thomas Wolfel
IPC分类号： A61K39/395 , C07K16/18 , C07H21/04 , A61K39/39 , A61P35/00 , C12N15/64 , C12N1/00
CPC分类号： A61K39/0011 , A61K38/1774 , A61K2039/57 , A61K2039/572 , A61K2039/585 , C07K14/4748 , C07K16/3053
摘要： The present invention relates to certain melanoma-associated oligopeptides that are recognized by CD8-positive cytotoxic T-lymphocytes (CTLs) as peptide antigen and which elicit a CTL-induced lysis and/or apoptosis of tumor cells. The present invention also relates to the use of these melanoma-associated oligopeptides in cancer therapy.
摘要翻译：本发明涉及由CD8阳性细胞毒性T淋巴细胞（CTLs）识别为肽抗原并引起CTL诱导的肿瘤细胞裂解和/或凋亡的某些黑素瘤相关寡肽。本发明还涉及这些黑素瘤相关寡肽在癌症治疗中的用途。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式